ClinicalTrials.gg
TerminatedNCT05179239Updated Apr 15, 2025

A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer

A Phase 3 interventional study of SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102 and SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102 in Cervical Cancer, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Terminated at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-15.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor develops strategy adjustment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 455 studies in Uterine Cervical Neoplasms with a site in China — 205 open to participants now, 240 under way, 35 of them phase 3. Uterine Cervical Neoplasms · China.

Enrollment
277th of 360
31 · median 90
Started
2022
with 61 others
Phase 3
56 of 455
21 open now
Registered
197th of 455
by date

Among the 455 studies in Uterine Cervical Neoplasms with a site in China, this one is the 277th largest by enrollment of the 360 interventional ones that give a count, is one of 62 that started in 2022, is one of 56 in phase 3, and was the 197th registered.

Uterine Cervical Neoplasms

2,368 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

205 of the 455 studies in Uterine Cervical Neoplasms with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 474 Uterine Cervical Neoplasms studies recruiting now, 244 (51%) set no upper age limit and 190 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 455 studies in Uterine Cervical Neoplasms with a site in China, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy, and safety of SHR-1701 or Placebo Plus Chemotherapy With or Without BP102 (Bevacizumab) as First-Line Treatment in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer.

03

Conditions studied

  • Cervical Cancer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-70 years, female.
  2. With (ECOG) performance status scores of 0-1.
  3. With a of ≥ 12 weeks.
  4. Acute toxicities from prior anti-tumor treatments must have resolved to Grade 0-1 (per 5.0).
  5. With at least one as per v1.1.
  6. With confirmed squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma of the cervix.
  7. Persistent, recurrent, or cervical cancer.
  8. Patients to be enrolled in Stage II are required to provide a minimum of 10 slides of fresh (preferred).
  9. Women of must have a negative serum pregnancy test within 3 days prior to starting study treatment.
  10. Patients must agree and have signed the form.

Exclusion criteria

Exclusion Criteria:

  1. With known to paclitaxel, cisplatin, or carboplatin.
  2. With known allergies to any of the study drugs or their ; severe allergic reactions to other monoclonal antibodies.
  3. With inadequately treated .
  4. With uncontrolled hypertension.
  5. With uncontrolled cardiac diseases or symptoms.
  6. With major vascular disease.
  7. With arterial/venous thrombotic events within 6 months prior to randomization.
  8. Have received full-dose anticoagulant or hemolytic therapy within 10 days prior to randomization.
  9. With hemorrhage or definitive bleeding diathesis within 3 months prior to randomization.
  10. With severe, unhealed, or open wounds as well as active ulcers or untreated fractures.
  11. With any active disease or a history of autoimmune disease that is expected to recur.
  12. Had other active malignant tumors within 5 years prior to study enrolment.
  13. With congenital or acquired immunodeficiency (such as -infected patients).
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102

    Drug: SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102

  • Experimental
    SHR-1701 + paclitaxel + cisplatin/carboplatin ± BP102

    Drug: SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102

  • Placebo comparator
    Placebo + paclitaxel + cisplatin/carboplatin ± BP102

    Drug: Placebo + paclitaxel + cisplatin/carboplatin ± BP102

Interventions

  • DrugSHR-1701 + paclitaxel + cisplatin/carboplatin + BP102

    Drug page: BP102

    SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102

  • DrugSHR-1701 + paclitaxel + cisplatin/carboplatin± BP102

    Drug page: BP102

    SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102

  • DrugPlacebo + paclitaxel + cisplatin/carboplatin ± BP102

    Placebo + paclitaxel + cisplatin/carboplatin ± BP102

06

What researchers measure

Primary outcomes

  1. Incidence and severity of Participants Who Experience an Adverse Event (AE) as per NCI-CTC AE 5.0(Stage I)

    Time frame: Up to approximately 21 days

  2. Incidence and severity of Participants Who Experience a Serious AE (SAE) as per NCI-CTC AE 5.0(Stage I)

    Time frame: Up to approximately 21 days

  3. Incidence and severity of Participants Who Experience an Immune-related AE (irAE) as per NCI-CTC AE 5.0(Stage I)

    Time frame: Up to approximately 21 days

  4. BIRC-assessed progression-free survival (PFS) as per RECIST v1.1(Stage II)

    Time frame: Up to approximately 10 months

  5. OS is defined as the time from randomization to death due to any cause. (Stage II)

    Time frame: Up to approximately 26 months

Secondary outcomes

  1. Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by Investigator (Stage I)

    Time frame: Up to approximately 26 months

  2. Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Investigator (Stage I)

    Time frame: Up to approximately 26 months

  3. Disease Control Rate (DCR)up to approximately 26 months(Stage I)

    Time frame: up to approximately 26 months

  4. Duration of Response (DOR) Per RECIST 1.1 as Assessed by Investigator (Stage I)

    Time frame: Up to approximately 26 months

  5. Time to Progress(TTP) up to approximately 26 months(Stage I)

    The time from the date of the first medication to the date of the first recording of tumor progression (as measured according to THE RECIST v1.1 criteria, regardless of whether treatment is continued or not).

    Time frame: up to approximately 26 months

  6. Overall survival (OS) up to approximately 26 months(Stage I)

    Time frame: up to approximately 26 months

  7. Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by BIRC- and investigator(Stage II)

    Time frame: Up to approximately 26 months

  8. Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BIRC- and investigator(Stage II)

    Time frame: Up to approximately 26 months

  9. Disease Control Rate (DCR)Per RECIST 1.1 as Assessed by BIRC- and investigator(Stage II)

    Time frame: Up to approximately 26 months

  10. Duration of Response (DOR) Per RECIST 1.1 as Assessed by BIRC- and investigator (Stage II)

    Time frame: Up to approximately 26 months

  11. Time to Progress(TTP) up to approximately 26 months (Stage II)

    The time from the date of randomization to the date of the first recording of tumor progression (as measured according to THE RECIST v1.1 criteria, regardless of whether treatment is continued or not).

    Time frame: up to approximately 26 months

  12. Incidence and severity of Participants Who Experience an Adverse Event (AE) as per NCI-CTC AE 5.0 (Stage II)

    Time frame: Up to approximately 26 months

  13. Incidence and severity of Participants Who Experience a Serious AE (SAE) as per NCI-CTC AE 5.0(Stage II)

    Time frame: Up to approximately 26 months

  14. Incidence and severity of Participants Who Experience an Immune-related AE (irAE) as per NCI-CTC AE 5.0(Stage II)

    Time frame: Up to approximately 26 months.

07

Study locations

1 site
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Aug 2024, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2021
First posted
Jan 5, 2022
StartActual
Feb 26, 2022
Primary completionActual
Aug 12, 2024
CompletionActual
Aug 12, 2024
Last update
Apr 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05179239
Responsible party
Sponsor
First posted
Jan 5, 2022
Start date
Feb 26, 2022
Primary completion
Aug 12, 2024
Completion
Aug 12, 2024
Last update
Apr 15, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BP102

Start the discussion